FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine

By: via Benzinga
Merck (NYSE: MRK ), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Today's Merck is a global
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.